Flanvotumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Flanvotumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetHGF
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6470H9986N1714O2018S46
Molar mass145.5 kg/mol g·mol−1
 ☒N☑Y (what is this?)  (verify)

Flanvotumab, also known as IMC-20D7S, is a human monoclonal antibody designed for the treatment of melanoma.[1] It targets TYRP1.[2]

Flanvotumab was developed by ImClone Systems, now owned by Eli Lilly.[3]

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Flanvotumab" (PDF). American Medical Association.
  2. ^ http://adisinsight.springer.com/drugs/800019264
  3. ^ http://adisinsight.springer.com/drugs/800019264